The most dangerous mistake is assuming that completion means readiness.
A representative may finish every module and pass every assessment yet still struggle with an HCP. As launches grow more complex and access becomes limited, pharma organisations must look beyond activity metrics.
This article explores the gaps in traditional training measures and how Capability and Enablement teams can build field confidence, consistency, and performance.
Pharma companies invest heavily in launches, field teams, content, and capability development. Most already have structured training programmes, LMS modules, product sessions, certification processes, manager coaching, and approved materials in place.
Most companies are not short of training activity. The harder question is whether that activity is creating representatives who are genuinely ready for real HCP conversations.
For Commercial Capability and Enablement teams, this is becoming a more urgent question. The market is moving faster, launch windows are tighter, HCP access is more limited, and field teams are expected to use increasingly complex scientific and approved content with confidence and consistency.
A representative can complete training and still struggle in the field. They can pass an assessment and still freeze during an objection. They can attend a product session and still avoid using approved content in a live HCP conversation.
Every launch team has experienced the frustration of seeing representatives complete training successfully, only to discover that confidence disappears when the first difficult HCP objection appears.
That is the gap between learning completion and field readiness.
Increasingly, leading pharma companies are using AI simulations to create practice opportunities that managers simply cannot provide at scale.
Why Readiness Matters More Than Ever
Ten years ago, representatives could learn in the field. Today, product launches are more complex, scientific discussions are deeper, and access opportunities are fewer. Organisations have fewer chances to get interactions right, making readiness before field deployment more important than ever.
In parallel, field teams are expected to absorb increasing volumes of scientific information, navigate stricter compliance requirements, and communicate confidently across multiple channels. Learning on the job remains important, but organisations can no longer rely on experience alone to close capability gaps. The cost of being unprepared is simply higher than it used to be.
Why Completion Is No Longer Enough
Most learning platforms are effective at tracking participation. They can show who attended a session, who completed a module, who passed a knowledge check, and who downloaded a piece of content.
Those measures are useful, but they do not prove that a representative is ready to perform under pressure.
True readiness shows up in the conversation itself. It is the ability to explain clinical value clearly, respond to objections, adapt the message to the HCP, stay within approved boundaries, and use content naturally rather than mechanically.
For Commercial Capability and Enablement teams, the challenge is no longer only to deliver learning. It is to close the gap between knowledge and execution.
Slow Ramp-Up Puts Pressure on Enablement
New representatives represent a significant investment from day one. Yet Pharmaceutical Executive has reported that new sales representatives take an average of 11.2 months to become fully productive.¹ Salesforce’s State of Sales Report also identifies sales enablement and training as key growth levers for sales leaders.²
For training leaders and managers, this creates a practical challenge. It is not enough to provide information. Representatives need repeated practice, feedback, and confidence before they are ready to engage effectively with HCPs.
The longer readiness takes, the more pressure sits on onboarding programmes, managers, and field coaching.
Managers Cannot Carry the Whole Coaching Burden
Manager coaching remains one of the most important parts of field development, but it cannot be the only mechanism for building readiness.
Managers are expected to support launches, review performance, develop people, and coach representatives. Even in high-performing organisations, coaching capacity is limited.
AI-enabled simulation gives representatives opportunities to practise realistic HCP conversations, repeat difficult scenarios, and receive structured feedback before manager time is required.
This allows managers to focus on higher-value coaching: judgement, strategy, and performance improvement.
Approved Content Still Needs Confidence Behind It
Pharma companies invest heavily in approved content. Medical review, legal approval, scientific messaging, localisation, campaign development, and omnichannel planning all require significant investment.
However, content only creates value when it becomes part of real HCP conversations.
Veeva has reported that field teams use content in fewer than half of HCP meetings and that nearly 80% of approved content is rarely or never used.³ Veeva Pulse Field Trends data also shows that HCP engagements with shared content result in more than double the new patient treatment starts.⁴
For Commercial Capability and Enablement teams, this matters. Content adoption is not only a distribution problem. It is often a confidence problem.
Representatives need to know when to use content, how to connect it to HCP needs, and how to remain compliant while sounding fluent and credible.
Content only creates value when representatives are ready to use it.
HCP Conversations Are Becoming Harder to Get Right
HCP access continues to become more competitive. ZS has described access as being ‘at a premium’, particularly in oncology, while IQVIA notes that healthcare professionals are increasingly overstretched and harder to reach.⁵⁻⁶
This increases the importance of every interaction. Representatives need to be prepared before they enter the conversation, not after mistakes have already been made in the field.
When representatives struggle with objections, clinical discussions, or content usage, the issue is often a readiness gap rather than a knowledge gap.
Readiness Needs to Be Measured Differently
Most organisations can report who completed training. Far fewer can confidently answer a more important question: which representatives are genuinely ready for their next HCP conversation?
The next step for Capability and Enablement teams is not simply more training. Most companies already have enough learning activity.
The bigger shift is measurement.
Completion rates, attendance, knowledge checks, and LMS data still have a place. They show participation. They do not show whether someone is ready for a high-value HCP conversation.
Readiness needs to be assessed closer to the behaviours that matter in the field. Can the representative handle objections? Can they explain the science accurately? Can they use approved content appropriately? Can they adapt without going off message? Can they remain confident under pressure?
These are the signals that matter.
AI simulation makes this more practical because representatives can practise realistic scenarios repeatedly and receive feedback before they are in front of an HCP. It also gives Capability and Enablement teams a clearer view of where the gaps are: by product, region, team, objection type, content area, or confidence level.
That kind of visibility is difficult to get from completion data alone.
Why AI Changes the Role of Capability and Enablement Teams
AI does not make Capability and Enablement teams less important. It makes them more strategic.
Historically, these functions have been measured on delivery: programmes launched, modules completed, and content distributed. Increasingly, organisations need visibility into readiness and performance.
AI-enabled readiness helps connect learning activity to field behaviours. It allows organisations to identify capability gaps earlier and focus support where it creates the greatest impact.
Salesforce has reported that sales teams using AI are more likely to report revenue growth, while IQVIA argues that the future of field engagement will be increasingly insight-driven and digitally supported.⁷⁻⁸
The Risk of Staying with Activity Metrics
The most dangerous mistake is assuming that completion means readiness.
It does not.
A completed module does not guarantee confidence. A passed assessment does not guarantee fluency. Attendance at a training session does not guarantee that a representative can manage a difficult HCP conversation.
If readiness gaps are not identified inside the organisation, they will eventually appear in the field. They show up in inconsistent execution, unused content, weak objection handling, avoidable manager burden, and slower ramp-up.
For Capability and Enablement teams, that is both a challenge and an opportunity. The challenge is that traditional training metrics are no longer enough on their own. The opportunity is that readiness can become one of the most valuable contributions they make to commercial performance.
A Readiness Question, Not Just a Training Question
Pharma does not need more learning activity for the sake of it. It needs field teams that can apply knowledge confidently, consistently, and compliantly in real HCP conversations.
That is what readiness means.
For Capability and Enablement leaders, this brings the work much closer to the field. Training only matters if representatives can use it in the conversations that build confidence, trust, and influence HCP decisions.
For years, organisations have measured whether training happened. The next challenge is proving that representatives are ready to perform.
References.
¹ Pharmaceutical Executive, ‘The Top Priority for Sales Leaders: Improving Sales Enablement and Training in Pharma’.
https://www.pharmexec.com/view/priority-sales-leaders-improving-enablement-training
² Salesforce, ‘State of Sales Report – Sixth Edition’.
³ Veeva, ‘Veeva Pulse Report Finds Content-Driven Engagement Lags Despite Proven Boost to Treatment Adoption’.
⁴ Veeva, ‘Veeva Pulse Field Trends Report’.
https://www.veeva.com/resources/veeva-pulse-field-trends-report-1q25/
⁵ ZS, ‘Oncology sales planning: Strategies amid access and competition’.
https://www.zs.com/insights/restricted-access-pharma-reps-rethinking-sales-planning-oncology
⁶ IQVIA, ‘From Preference To Practice: Understanding The Evolving Channel Preferences of Healthcare Professionals’.
https://www.iqvia.com/locations/emea/blogs/2025/11/from-preference-to-practice
⁷ Salesforce, ‘Salesforce Report: Sales Teams Using AI 1.3x More Likely to See Revenue Increase’.
https://www.salesforce.com/news/stories/sales-ai-statistics-2024/
⁸ IQVIA, ‘Driving Field Force Excellence in Pharma with Agentic AI and Digital Agents’.
https://www.iqvia.com/blogs/2025/07/driving-field-force-excellence-in-pharma
About the Author
Marina Hickson is Managing Director of Vivanti, a life sciences AI and enablement company. Vivanti’s AVA Trainer platform helps pharmaceutical organisations build field readiness through AI-powered simulations, coaching, and certification.
